Insulin resistance, abnormal energy metabolism and increased ischemic damage in the chronically infarcted rat heart

Cardiovascular Research

Volumn 71, Issue 1, 2006, Pages 149-157

  Murray, Andrew J ^a   Lygate, Craig A ^b   Cole, Mark A ^a   Carr, Carolyn A ^a   Radda, George K ^a   Neubauer, Stefan ^b   Clarke, Kieran ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Energy metabolism; Heart failure; Infarction; Insulin resistance; Ischemia

Indexed keywords

ADENOSINE TRIPHOSPHATE; FATTY ACID; GLUCOSE TRANSPORTER 4; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; ENERGY METABOLISM; GLUCOSE TRANSPORT; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE ISCHEMIA; HEART PERFUSION; HYDROLYSIS; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISOLATED HEART; MALE; NONHUMAN; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RAT STRAIN;

ADENOSINE TRIPHOSPHATE; ANIMALS; ECHOCARDIOGRAPHY; ENERGY METABOLISM; FATTY ACIDS, NONESTERIFIED; GLUCOSE; GLUCOSE TRANSPORTER TYPE 4; GLYCOGEN; INSULIN; INSULIN RESISTANCE; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MODELS, ANIMAL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PERFUSION; RATS; RATS, WISTAR; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33744913519     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cardiores.2006.02.031     Document Type: Article

References (53)

1. Braunwald E. Congestive heart failure: a half century perspective. Eur Heart J 22 (2001) 825-836
2. Neubauer S., Krahe T., Schindler R., Horn M., Hillenbrand H., Entzeroth C., et al. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation 86 (1992) 1810-1818
3. Neubauer S., Horn M., Cramer M., Harre K., Newell J., Peters W., et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 96 (1997) 2190-2196
4. Horn M., Remkes H., Stromer H., Dienesch C., and Neubauer S. Chronic phosphocreatine depletion by the creatine analogue beta-guanidinopropionate is associated with increased mortality and loss of ATP in rats after myocardial infarction. Circulation 104 (2001) 1844-1849
5. Neubauer S., and Clarke K. Cardiac energy metabolism in heart failure. In: Marber M. (Ed). Cardiac metabolism and ischaemic cardiomyopathy (2003), Wolters Kluwer Health, Puteaux 45-61
6. Cross H., Opie L., Radda G., and Clarke K. Is a high glycogen content beneficial or detrimental to the ischemic rat heart? A controversy resolved. Circ Res 78 (1996) 482-491
7. Tian R., and Abel E. Responses of GLUT4-deficient hearts to ischemia underscore the importance of glycolysis. Circulation 103 (2001) 2961-2966
8. Liao R., Jain M., Cui L., D'Agostino J., Aiello F., Luptak I., et al. Cardiac-specific overexpression of GLUT1 prevents the development of heart failure attributable to pressure overload in mice. Circulation 106 (2002) 2125-21231
9. Paolisso G., De Riu S., Marrazzo G., Verza M., Varricchio M., and D'Onofri F. Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure. Metabolism 40 (1991) 972-977
10. Swan J., Anker S., Walton C., Godsland I., Clark A., Leyva F., et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. JACC 30 (1997) 527-532
11. Kemppainen J., Tsuchida H., Stolen K., Karlsson H., Bjornholm M., Heinonen O., et al. Insulin signalling and resistance in patients with chronic heart failure. J Physiol 550 (2003) 305-315
12. Paternostro G., Camici P., Lammerstma A., Marinho N., Baliga R., Kooner J., et al. Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease. J Clin Invest 98 (1996) 2094-2099
13. Paternostro G., Pagano D., Gneechi-Ruscone T., Bonser R., and Camici P. Insulin resistance in patients with cardiac hypertrophy. Cardiovasc Res 42 (1999) 246-253
14. Friehs I., Moran A., Stamm C., Colan S., Takeuchi K., Hung C.-D., et al. Impaired glucose transporter activity in pressure-overload hypertrophy is an early indicator of progression to failure. Circulation 100 suppl II (1999) 187-193
15. Murray A., Lygate C., Cole M., Hulbert K., Neubauer S., and Clarke K. Cardiac insulin resistance post-myocardial infarction. Circulation 108 (2003) IV-188 [Suppl]
16. Lygate C., Hulbert K., Monfared M., Cole M., Clarke K., and Neubauer S. The PPARgamma-activator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction. Cardiovasc Res 58 (2003) 632-637
17. King L., Sidell R., Wilding J., Radda G., and Clarke K. Free fatty acids, but not ketone bodies, protect diabetic hearts during low-flow ischemia. Am J Physiol 280 (2001) H1173-H1181
18. Sidell R., Cole M., Draper N., Desrois M., Buckingham R., and Clarke K. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart. Diabetes 51 (2002) 1110-1117
19. Neubauer S., Horn M., Naumann A., Tian R., Hu K., Laser M., et al. Impairment of energy metabolism in intact residual myocardium of rat hearts with chronic myocardial infarction. J Clin Invest 95 (1995) 1092-1100
20. Bergmeyer H. Methods of enzymatic analysis (1974), Academic Press, New York
21. Neubauer S., Horn M., Laser M., Huegel S., Gaudron P., Hu K., et al. Exacerbation of hypoxia/reoxygenation injury in chronically infarcted rat hearts. A 31P-NMR study. Circulation 86 (1992) I-338 [Suppl]
22. Hugel S., Horn M., de Groot M., Remkes H., Dienesch C., Hu K., et al. Effects of ACE inhibition and beta-receptor blockade on energy metabolism in rats postmyocardial infarction. Am J Physiol 277 (1999) H2167-H2175
23. Ingwall J.S., and Weiss R.G. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res 95 (2004) 135-145
24. Stanley W.C., Recchia F.A., and Lopaschuk G.D. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85 (2005) 1093-1129
25. Doehner W., Rauchhaus M., Ponikowski P., Godsland I.F., von Haehling S., Okonko D.O., et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 46 (2005) 1019-1026
26. Paternostro G., Clarke K., Heath J., Seymour A.-M., and Radda G. Decreased GLUT-4 mRNA content and insulin-sensitive deoxyglucose uptake show insulin resistance in the hypertensive rat heart. Cardiovasc Res 30 (1995) 205-211
27. Nikolaidis L.A., Sturzu A., Stolarski C., Elahi D., Shen Y.T., and Shannon R.P. The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. Cardiovasc Res 61 (2004) 297-306
28. Lommi J., Kupari M., Koskinen P., Naveri H., Leinonen H., Pulkki K., et al. Blood ketone bodies in congestive heart failure. J Am Coll Cardiol 28 (1996) 665-672
29. Lei B., Lionetti V., Young M., Chandler M., d'Agostino C., Kang E., et al. Paradoxical downregulation of the glucose oxidation pathway despite enhanced flux in severe heart failure. J Mol Cell Cardiol 36 (2004) 567-576
30. Murray A.J., Anderson R.E., Watson G.C., Radda G.K., and Clarke K. Uncoupling proteins in human heart. Lancet 364 (2004) 1786-1788
31. Perseghin G., Ghosh S., Gerow K., and Shulman G.I. Metabolic defects in lean nondiabetic offspring of NIDDM parents: a cross-sectional study. Diabetes 46 (1997) 1001-1009
32. Shulman G.I. Cellular mechanisms of insulin resistance. J Clin Invest 106 (2000) 171-176
33. Gilde A., van der Lee K., Willemsen P., Chinetti G., van der Leij F., van der Vusse G., et al. Peroxisome proliferator-activated receptor (PPAR) alpha and PPAR beta/delta, but not PPAR gamma, modulate the expression of genes involved in cardiac lipid metabolism. Circ Res 92 (2003) 518-524
34. Vettor R., Fabris R., Serra R., Lombardi A., Tonello C., Granzotto M., et al. Changes in FAT/CD36, UCP2, UCP3 and GLUT4 gene expression during lipid infusion in rat skeletal and heart muscle. Int J Obesity 26 (2002) 838-847
35. Panagia M., Gibbons G.F., Radda G.K., and Clarke K. PPAR-alpha activation required for decreased glucose uptake and increased susceptibility to injury during ischemia. Am J Physiol, Heart Circ Physiol 288 (2005) H2677-H2683
36. Finck B.N., Bernal-Mizrachi C., Han D.H., Coleman T., Sambandam N., LaRiviere L.L., et al. A potential link between muscle peroxisome proliferator-activated receptor-alpha signaling and obesity-related diabetes. Cell Metab 1 (2005) 133-144
37. Iwanaga Y., Hoshijima M., Gu Y., Iwatate M., Dieterle T., Ikeda Y., et al. Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J Clin Invest 113 (2004) 727-736
38. King L., Sidell R., Jones B., Radda G., and Clarke K. Fatty acids, ischaemic damage and the diabetic heart. MAGMA 6 (1998) 173-174
39. Hue L., Beauloye C., Marsin A.-S., Bertrand L., Horman S., and Rider M. Insulin and ischemia stimulate glycolysis by acting on the same targets through different and opposing pathways. J Mol Cell Cardiol 34 (2002) 1091-1097
40. Yang J., and Holman G.D. Insulin and contraction stimulate exocytosis, but increased AMP-activated protein kinase activity resulting from oxidative metabolism stress slows endocytosis of GLUT4 in cardiomyocytes. J Biol Chem 280 (2005) 4070-4078
41. Dennis S., Gevers W., and Opie L. Protons in ischemia: where do they come from; where do they go to?. J Mol Cell Cardiol 23 (1991) 1077-1086
42. Batist G., Mersereau W., Malashenko B.A., and Chiu R.C. Response to ischemia-reperfusion injury in hypertrophic heart. Role of free-radical metabolic pathways. Circulation 80 (1989) III10-III13
43. Morgan E.E., Rennison J.H., Young M.E., McElfresh T.A., Kung T.A., Tserng K.Y., et al. Effects of chronic activation of peroxisome proliferator activated receptor alpha or high fat feeding in a rat infarct model of heart failure. Am J Physiol, Heart Circ Physiol (2005)
44. Lehman J., and Kelly D. Transcriptional activation of energy metabolic switches in the developing and hypertrophied heart. Clin Exp Pharmacol Physiol 29 (2002) 339-345
45. Osorio J., Stanley W., Linke A., Castellari M., Diep Q., Panchal A., et al. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation 106 (2002) 606-612
46. Sack M., Rader T., Park S., Bastin J., McCune S., and Kelly D. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 94 (1996) 2837-2842
47. Barger P., and Kelly D. Fatty acid utilization in the hypertrophied and failing heart: molecular regulatory mechanisms. Am J Med Sci 318 (1999) 36-42
48. Davila-Roman V., Vedala G., Herrero P., delasFuentes L., Rogers J., Kelly D., et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. JACC 40 (2002) 271-277
49. Wittels B., and Spann Jr. J. Defective lipid metabolism in the failing heart. J Clin Invest 47 (1968) 1787-1794
50. Chandler M.P., Kerner J., Huang H., Vazquez E., Reszko A., Martini W.Z., et al. Moderate severity heart failure does not involve a downregulation of myocardial fatty acid oxidation. Am J Physiol, Heart Circ Physiol 287 (2004) H1538-H1543
51. Bishop S., and Altschuld R. Increased glycolytic metabolism in cardiac hypertrophy and congestive failure. Am J Physiol 218 (1970) 153-159
52. Razeghi P., Young M., Alcorn J., Moravec C., Frazier O., and Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation 104 (2001) 2923-2931
53. Seymour A.-M., and Chatham J. The effects of hypertrophy and diabetes on cardiac pyruvate dehydrogenase activity. J Mol Cell Cardiol 29 (1997) 2771-2778